**How to access the ReFRAME Library**

ReFRAME partnerships are determined on a case-by-case basis to avoid redundant screens, minimize compound consumption and ensure proposed assays have the requisite quality. Successful partner screens will meet the following requirements:

* Relevant to Global Health
* Execute a Material Transfer Agreement that ensures global access to data generated by the screen (12-month delay before deposition of data onto a public database maintained by Calibr (reframedb.org)
* Differentiated assay from prior or on-going screens (e.g. Pathogen species tested, clinical isolate vs. lab-adapted strain, lifecycle stage, assay readout (proliferation vs viability, etc.)
* Miniaturized and optimized to suit limited compound supply
  + Assay volume less than 50 μL (384- or 1536-well format)
  + Assay amenable to a single point screen and <1% hit rate follow-up

If approved, the typical screening partner receives ~0.5 nanomoles of each compound during primary screening (i.e., **50 nL @ 10 mM**) and up to 4 nanomoles for “hits” during the entire campaign (includes primary screen, dose response reconfirmation and counter screen).

For more information contact reframescreens@scripps.edu